Abstract
Discovery, isolation, biochemical/pharmacological characterization, pre-clinical and clinical trials of drugs derived from the marine environment are continuously developing and increasing. One of the most promising area is cancer therapy. Currently, there are two drugs approved by the Food and Drug Administration (FDA) and European Agency for the Evaluation of Medicinal Products (EMA) in cancer treatment, namely Cytarabine (Cytosar-U1®) and Eribulin (E7389 or Halaven®). Trabectedin (ET-743 or Yondelis1®), approved by EMA, is completing key Phase III studies in the U.S. for final approval. It was estimated that 118 marine natural products (MNPs) are currently in preclinical trials, 22 MNPs in clinical trials and 3 MNPs on the market. The characteristics and selectivity profiles of new drugs for cancer therapy, as well as drugs disclosed in related patent applications, will be the focus of this review, providing a brief and ready to use reference.
Keywords: Anticancer therapy, clinical trials cancer, human diseases, marine drugs, mechanism of action, multitargets, patent
Recent Patents on Anti-Cancer Drug Discovery
Title:Anticancer Drug Discovery from the Marine Environment
Volume: 7 Issue: 2
Author(s): Candida Nastrucci, Alfredo Cesario and Patrizia Russo
Affiliation:
Keywords: Anticancer therapy, clinical trials cancer, human diseases, marine drugs, mechanism of action, multitargets, patent
Abstract: Discovery, isolation, biochemical/pharmacological characterization, pre-clinical and clinical trials of drugs derived from the marine environment are continuously developing and increasing. One of the most promising area is cancer therapy. Currently, there are two drugs approved by the Food and Drug Administration (FDA) and European Agency for the Evaluation of Medicinal Products (EMA) in cancer treatment, namely Cytarabine (Cytosar-U1®) and Eribulin (E7389 or Halaven®). Trabectedin (ET-743 or Yondelis1®), approved by EMA, is completing key Phase III studies in the U.S. for final approval. It was estimated that 118 marine natural products (MNPs) are currently in preclinical trials, 22 MNPs in clinical trials and 3 MNPs on the market. The characteristics and selectivity profiles of new drugs for cancer therapy, as well as drugs disclosed in related patent applications, will be the focus of this review, providing a brief and ready to use reference.
Export Options
About this article
Cite this article as:
Nastrucci Candida, Cesario Alfredo and Russo Patrizia, Anticancer Drug Discovery from the Marine Environment, Recent Patents on Anti-Cancer Drug Discovery 2012; 7 (2) . https://dx.doi.org/10.2174/157489212799972963
DOI https://dx.doi.org/10.2174/157489212799972963 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Herpesvirus / Retrovirus Chimeric Vectors
Current Gene Therapy Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology Engineered Exosomes: A Promising Drug Delivery Strategy for Brain Diseases
Current Medicinal Chemistry Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.
Current Gene Therapy Dual Targeting of Autophagy and NF-κB Pathway by PPARγ Contributes to the Inhibitory Effect of Demethoxycurcumin on NLRP3 Inflammasome Priming
Current Molecular Pharmacology HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Effect of MRJF4 on C6 Glioma Cells Proliferation and Migration
Central Nervous System Agents in Medicinal Chemistry Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued) Graphene Oxide-Based Nanocarriers for Cancer Imaging and Drug Delivery
Current Pharmaceutical Design Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets
Current Neuropharmacology Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Clinical and <i>In Silico</i> Outcomes of the Expression of miR-130a-5p and miR-615-3p in Tumor Compared with Non-Tumor Adjacent Tissues of Patients with BC
Anti-Cancer Agents in Medicinal Chemistry Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
Current Cancer Drug Targets Induction of Antitumor Immune Responses with Recombinant Lentivector: Role of Skin Derived DCs
Current Cancer Therapy Reviews